Endometrial Cancer Treatment Market Report 2026

Endometrial Cancer Treatment Market Overview

• Endometrial Cancer Treatment market size has reached to $32.09 billion in 2025 • Expected to grow to $43.44 billion in 2030 at a compound annual growth rate (CAGR) of 6.4% • Growth Driver: Rising Prevalence Of Endometrial Cancer Through Advances In The Endometrial Cancer Treatment Market • Market Trend: PD-1 Immunotherapy Breakthrough Transforms Advanced Endometrial Cancer Treatment Landscape • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Endometrial Cancer Treatment Market?

Endometrial cancer treatment refers to the medical interventions aimed at managing and potentially curing cancer that develops in the lining of the uterus. The main types of endometrial cancer treatment market are adenocarcinoma, uterine carcinosarcoma, squamous cell carcinoma, small cell carcinoma, transitional carcinoma, serous carcinoma, and other types. Adenocarcinoma refers to a type of cancer that originates in the glandular cells of a particular organ or tissue in the body. Endometrial cancer treatment is used for treating adenocarcinoma by surgery, radiation therapy, chemotherapy, hormonal therapy, targeted therapy, or a combination of these approaches. The various diagnosis includes biopsy, pelvic ultrasound, hysteroscopy, CT scan, and other diagnostic methods. The endometrial cancer treatment is administered either orally or intravenously and they are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Endometrial Cancer Treatment Market Growth Forecast?

The endometrial cancer treatment market size is expected to see strong growth in the next few years. It will grow to $43.44 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to advancements in genomics and precision medicine, increased adoption of ai-driven diagnostics, growth in targeted and immunotherapy drugs, rising geriatric population, improved healthcare infrastructure. Major trends in the forecast period include personalized treatment approaches, minimally invasive surgical techniques, targeted therapy development, combination therapy strategies, enhanced patient monitoring and follow-up.

Global Endometrial Cancer Treatment Market Segmentation

1) By Type: Adenocarcinoma, Uterine Carcinosarcoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Transitional Carcinoma, Serous Carcinoma, Other Types 2) By Diagnosis Method: Biopsy, Pelvic Ultrasound, Hysteroscopy, CT Scan, Other Diagnosis Methods 3) By Route Of Administration: Oral, Intravenous 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Adenocarcinoma: Endometrioid Adenocarcinoma, Non-Endometrioid Adenocarcinoma 2) By Uterine Carcinosarcoma: High-Grade Uterine Carcinosarcoma, Low-Grade Uterine Carcinosarcoma 3) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma 4) By Small Cell Carcinoma: Small Cell Neuroendocrine Carcinoma 5) By Transitional Carcinoma: Transitional Cell Carcinoma Of The Uterus 6) By Serous Carcinoma: High-Grade Serous Carcinoma, Low-Grade Serous Carcinoma 7) By Other Types: Mixed Cell Type Carcinomas, Undifferentiated Carcinoma, Other Rare Histological Types

What Is The Driver Of The Endometrial Cancer Treatment Market?

The growing prevalence of endometrial cancer is expected to propel the growth of the endometrial cancer treatment market going forward. The prevalence of endometrial cancer refers to an increase in the number of cases of endometrial cancer within a specific population or over a certain period. This shift has resulted from changes in risk factors, improved detection and diagnosis methods, increased awareness, and an aging population. Endometrial cancer treatments help in early endometrial cancer detection, providing targeted therapies, prevention of recurrence, and clinical trials and research studies to improve treatment options. As the prevalence of endometrial cancer continues to rise and advancements in treatment options expand the endometrial cancer treatment market is expected to grow. For instance, in 2023, according to Cancer.Net, a website that provides oncologist-approved cancer information, an estimated 66,200 people in the United States will be diagnosed with uterine, or endometrial cancer. Therefore, the rise in prevalence of endometrial cancer is driving the growth of the endometrial cancer treatment industry.

Key Players In The Global Endometrial Cancer Treatment Market

Major companies operating in the endometrial cancer treatment market are Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi-Aventis, Teva Pharmaceutical Industries Limited, AstraZeneca plc, Pfizer Inc., Bristol-Myers Squibb Company, Eisai Co. Ltd., AbbVie Inc., Roche Holding AG, Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Bayer AG, Eli Lilly and Company, Varian Medical Systems Inc., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., Stemline Therapeutics Inc.

Global Endometrial Cancer Treatment Market Trends and Insights

Major companies operating in the endometrial cancer treatment market are focusing on developing advanced solutions such as PD-1 pathway blocking immunotherapy to enhance treatment effectiveness and durability of response. PD-1 pathway-blocking immunotherapy works by preventing cancer cells from using the PD-1 mechanism to evade immune detection, and it enables immune cells to recognize and attack tumors with greater precision. This approach offers a targeted option in advanced or recurrent disease where chemotherapy has often provided limited long-term benefit. For instance, in August 2025, GSK Plc, a UK-based biopharma company, launched Jemperli, featuring a PD-1 blocking mechanism. The therapy is India’s first approved immunotherapy for second-line treatment of mismatch repair deficient or microsatellite instability high advanced endometrial cancer, and it has shown an objective response rate of 45.5 percent in the GARNET trial. It maintains high probabilities of sustained response at 12 and 24 months and offers an acceptable safety profile. The launch addresses a critical unmet need in India, where many patients present with advanced disease and require more effective and predictable treatment options.

What Are Latest Mergers And Acquisitions In The Endometrial Cancer Treatment Market?

In February 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired MorphoSys for $2.9 billion. This acquisition of MorphoSys enables Novartis to access innovative treatments, particularly pelabresib (CPI-0610), which is under development for myelofibrosis, a rare blood cancer. MorphoSys AG is a Germany-based biopharmaceutical company developing innovative medicines in oncology.

Regional Insights

North America was the largest region in the endometrial cancer treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global endometrial cancer treatment market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Endometrial Cancer Treatment Market?

The endometrial treatment market includes revenues earned by entities by providing drugs, medications, diagnostic devices, radiation therapy equipment, surgical instruments, and devices. Therapies that are used in the treatment of endometrial cancer. The endometrial treatment market includes surgery, radiation therapy, chemotherapy, hormonal therapy, targeted therapy, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Endometrial Cancer Treatment Market Report 2026?

The endometrial cancer treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the endometrial cancer treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.